Eurogentec Announces Agreement to Acquire AnaSpec, Inc.

"Bringing AnaSpec into the Eurogentec Group is a strategic decision for our company," explains Jean-Pierre Delwart, CEO of Eurogentec. "Through this acquisition, Eurogentec becomes a leading integrated solution provider for the Life Science and Diagnostics sectors. Our combined expertise enables Eurogentec to provide innovative solutions in the fields of Genomics and Proteomics for basic research in the biotech and pharmaceutical sectors, as well as applied solutions in the diagnostics sector. As an example, the HiLyte Fluor(TM) dyes and QXL(TM) quenchers that are part of AnaSpec's high performance detection assays will be integrated into Eurogentec's comprehensive portfolio of oligonucleotides. This will establish a license-friendly alternative to most dye-labeled oligonucleotides from competitors for commercial and diagnostic applications. Moreover, AnaSpec considerably strengthens Eurogentec's geographical presence in the US and Eurogentec will directly market and support AnaSpec's products in the EU." The founders of AnaSpec, Anita Hong, President, and Frank Hong, CEO, comment: "It is important for the sustained development of AnaSpec to integrate into a larger organization where its current assets and competencies can bring real added value. The total complementarities between Eurogentec's and AnaSpec's existing businesses and the cross-fertilization opportunities for future developments are a key factor for the success of this partnership. We are very much looking forward to closely working with the Eurogentec Team from this perspective."

AnaSpec's founders and senior management, Anita and Frank Hong, will remain aboard the Company in leading roles in continuing to grow AnaSpec's businesses, further expanding the high value detection reagents focus and facilitating integration with Eurogentec. Eurogentec intends to maintain the Company's state-of-the-art Fremont facility, to which AnaSpec recently moved operations, and its valued employees.

Troutman Sanders LLP served as legal counsel, and Achelous Partners, LLC, served as financial advisers to AnaSpec. DLA Piper LLP served as legal counsel to Eurogentec on this transaction.

ABOUT EUROGENTEC

Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertise in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec's Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.

Eurogentec is a privately-held company headquartered in Liege, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland, and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

SOURCE: AnaSpec, Inc.

AnaSpec, Inc. 
Albert Olson Hong, Business Development Specialist, 800-452-5530 ext. 243 
albertoh@anaspec.com 
or 
Eurogentec 
Jean-Pierre Delwart, Chief Executive Officer, +32-475-607-884 
Philippe Cronet, Chief Scientific Officer, +32-4-372-7411